Immunome (NASDAQ:IMNM) CFO Max Rosett Sells 65,000 Shares of Stock
by Danessa Lincoln · The Markets DailyImmunome, Inc. (NASDAQ:IMNM – Get Free Report) CFO Max Rosett sold 65,000 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the sale, the chief financial officer owned 54,037 shares of the company’s stock, valued at approximately $1,184,491.04. This represents a 54.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Immunome Price Performance
IMNM opened at $21.84 on Friday. The business has a 50 day simple moving average of $22.34 and a two-hundred day simple moving average of $19.22. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -9.02 and a beta of 2.13. Immunome, Inc. has a one year low of $5.15 and a one year high of $27.65.
Immunome (NASDAQ:IMNM – Get Free Report) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). As a group, sell-side analysts expect that Immunome, Inc. will post -2.21 EPS for the current fiscal year.
Institutional Trading of Immunome
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC increased its stake in shares of Immunome by 3,513.0% during the third quarter. Nisa Investment Advisors LLC now owns 80,426 shares of the company’s stock valued at $942,000 after purchasing an additional 78,200 shares in the last quarter. Nan Fung Trinity HK Ltd. raised its stake in Immunome by 7.9% during the third quarter. Nan Fung Trinity HK Ltd. now owns 592,103 shares of the company’s stock valued at $6,934,000 after buying an additional 43,253 shares during the last quarter. Kennedy Capital Management LLC boosted its holdings in Immunome by 642.6% in the second quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock worth $1,017,000 after acquiring an additional 94,627 shares in the last quarter. NEOS Investment Management LLC boosted its holdings in Immunome by 40.5% in the third quarter. NEOS Investment Management LLC now owns 162,186 shares of the company’s stock worth $1,899,000 after acquiring an additional 46,755 shares in the last quarter. Finally, Tema Etfs LLC purchased a new stake in shares of Immunome in the second quarter worth $1,074,000. 44.58% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on IMNM. Guggenheim boosted their price objective on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Leerink Partners set a $40.00 target price on shares of Immunome in a research note on Monday, December 15th. HC Wainwright began coverage on shares of Immunome in a research report on Thursday, February 12th. They set a “buy” rating and a $40.00 price target on the stock. Craig Hallum raised their price objective on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Thursday, January 22nd. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.45.
Read Our Latest Research Report on IMNM
Immunome Company Profile
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.